1. Picard C, Al-Herz W, Bousfiha A, Casanova JL, Chatila T, Conley ME, et al. Primary immunodeficiency diseases: an update on the classification from the international union of immunological societies expert committee for primary immunodeficiency 2015. J Clin Immunol 2015; 35: 696-726.
2. Amaya-Uribe L, Rojas M, Azizi G, Anaya JM, Gershwin ME. Primary immunodeficiency and autoimmunity: A comprehensive review. J Autoimmun 2019; 99: 52-72.
3. van der Fits L, van der Wel LI, Laman JD, Prens EP, Verschuren MC. Psoriatic lesional skin exhibits an aberrant expression pattern of interferon regulatory factor-2 (IRF-2). J Pathol 2003; 199: 107-114.
4. Gallo RL, Hooper LV. Epithelial antimicrobial defence of the skin and intestine. Nat Rev Immunol 2012; 12: 503-516.
5. Costagliola G, Cappelli S, Consolini R. Autoimmunity in primary immunodeficiency disorders: an updated review on pathogenic and clinical implications. J Clin Med 2021; 10: 4729.
6. Sakaguchi S, Yamaguchi T, Nomura T, Ono M. Regulatory T cells and immune tolerance. Cell 2008; 133: 775-787.
7. Lu LF, Thai TH, Calado DP, Chaudhry A, Kubo M, Tanaka K, et al. Foxp3-dependent microRNA155 confers competitive fitness to regulatory T cells by targeting SOCS1 protein. Immunity 2009; 30: 80-91.
8. Vignali DA, Collison LW, Workman CJ. How regulatory T cells work. Nat Rev Immunol 2008; 8: 523-532.
9. Collison LW, Workman CJ, Kuo TT, Boyd K, Wang Y, Vignali KM, et al. The inhibitory cytokine IL-35 contributes to regulatory T-cell function. Nature 2007; 450: 566-569.
10. Boothby IC, Cohen JN, Rosenblum MD. Regulatory T cells in skin injury: At the crossroads of tolerance and tissue repair. Sci Immunol 2020; 5: eaaz9631.
11. Dudda JC, Perdue N, Bachtanian E, Campbell DJ. Foxp3+ regulatory T cells maintain immune homeostasis in the skin. J Exp Med 2008; 205: 1559-1565.
12. Rosenblum MD, Gratz IK, Paw JS, Lee K, Marshak-Rothstein A, Abbas AK. Response to self antigen imprints regulatory memory in tissues. Nature 2011; 480: 538-542.
13. Josefowicz SZ, Lu LF, Rudensky AY. Regulatory T cells: Mechanisms of differentiation and function. Annu Rev Immunol 2012; 30: 531-564.
14. Ben-Skowronek I. IPEX syndrome: Genetics and treatment options. Genes (Basel) 2021; 12: 323.
15. Park H, Kim M, Lee K, Kim K, Jeon D, Kim Y, et al. Association between anxiety, depression and asthma. J Allergy Clin Immunol Pract 2011; 127: AB42.
16. Abbas AK, Benoist C, Bluestone JA, Campbell DJ, Ghosh S, Hori S, et al. Regulatory T cells: Recommendations to simplify the nomenclature. Nat Immunol 2013; 14: 307-308.
17. Szczawińska-Popłonyk A, Popłonyk N, Awdi K. Down syndrome in children: An inborn error of immunity with immune dysregulation. Children (Basel) 2024; 11: 1251.
18. Ohkura N, Sakaguchi S. A novel modifier of regulatory T cells. Nat Immunol 2009; 10: 685-686.
19. Lakkis FG. Immunology: TREG cells in transplantation-a double-edged sword? Nat Rev Nephrol 2014; 10: 185-186.
20. Belkaid Y, Hand TW. Role of the microbiota in immunity and inflammation. Cell 2014; 157: 121-141.
21. Gudjonsson JE, Johnston A, Sigmundsdottir H, Valdimarsson H. Immunopathogenic mechanisms in psoriasis. Clin Exp Immunol 2004; 135: 1-8.
22. Ruterbusch M, Pruner KB, Shehata L, Pepper M. In vivo CD4(+) T cell differentiation and function: Revisiting the Th1/Th2 paradigm. Annu Rev Immunol 2020; 38: 705-725.
23. Scharschmidt TC. Establishing tolerance to commensal skin bacteria: Timing is everything. Dermatol Clin 2017; 35: 1-9.
24. Grice EA, Segre JA. The skin microbiome. Nat Rev Microbiol 2011; 9: 244-253.
25. Abbas AK, Lichtman AH, Pillai S. Preface. Cellular and Molecular Immunology: Elsevier; 2010. p. v.
26. Di Vincenzo M, Diotallevi F, Piccirillo S, Carnevale G, Offidani A, Campanati A, et al. miRNAs, mesenchymal stromal cells and major neoplastic and inflammatory skin diseases: A page being written: A systematic review. Int J Mol Sci 2023; 24: 8502.
27. Gong Y, Tong J, Wang S. Are follicular regulatory T cells involved in autoimmune diseases? Front Immunol 2017; 8: 1790.
28. Eskandari SK, Daccache A, Azzi JR. Chimeric antigen receptor T(reg) therapy in transplantation. Trends Immunol 2024; 45: 48-61.
29. Belkaid Y, Tamoutounour S. The influence of skin microorganisms on cutaneous immunity. Nat Rev Immunol 2016; 16: 353-366.
30. Pasparakis M, Haase I, Nestle FO. Mechanisms regulating skin immunity and inflammation. Nat Rev Immunol 2014; 14: 289-301.
31. Kupper TS, Fuhlbrigge RC. Immune surveillance in the skin: mechanisms and clinical consequences. Nat Rev Immunol 2004; 4: 211-222.
32. Albanesi C, Scarponi C, Giustizieri ML, Girolomoni G. Keratinocytes in inflammatory skin diseases. Curr Drug Targets Inflamm Allergy 2005; 4: 329-334.
33. Soumelis V, Reche PA, Kanzler H, Yuan W, Edward G, Homey B, et al. Human epithelial cells trigger dendritic cell mediated allergic inflammation by producing TSLP. Nat Immunol 2002; 3:  673-680.
34. Proksch E, Brandner JM, Jensen JM. The skin: An indispensable barrier. Exp Dermatol 2008; 17: 1063-1072.
35. Scharschmidt TC, Vasquez KS, Truong HA, Gearty SV, Pauli ML, Nosbaum A, et al. A wave of regulatory T cells into neonatal skin mediates tolerance to commensal microbes. Immunity 2015; 43: 1011-1021.
36. Malissen B, Tamoutounour S, Henri S. The origins and functions of dendritic cells and macrophages in the skin. Nat Rev Immunol 2014; 14: 417-428.
37. Clausen BE, Stoitzner P. Functional specialization of skin dendritic cell subsets in regulating T cell responses. Front Immunol 2015; 6: 534.
38. Collin M, Milne P. Langerhans cell origin and regulation. Curr Opin Hematol 2016; 23: 28-35.
39. Coombes JL, Siddiqui KR, Arancibia-Carcamo CV, Hall J, Sun CM, Belkaid Y, et al. A functionally specialized population of mucosal CD103+ DCs induces Foxp3+ regulatory T cells via a TGF-beta and retinoic acid-dependent mechanism. J Exp Med 2007; 204: 1757-1764.
40. Iwasaki A, Medzhitov R. Regulation of adaptive immunity by the innate immune system. Science 2010; 327: 291-295.
41. Nestle FO, Kaplan DH, Barker J. Psoriasis. N Engl J Med 2009; 361: 496-509.
42. Belkaid Y, Harrison OJ. Homeostatic immunity and the microbiota. Immunity 2017; 46: 562-576.
43. Naik S, Bouladoux N, Linehan JL, Han SJ, Harrison OJ, Wilhelm C, et al. Commensal-dendritic-cell interaction specifies a unique protective skin immune signature. Nature 2015; 520: 104-108.
44. Pearce EL, Pearce EJ. Metabolic pathways in immune cell activation and quiescence. Immunity 2013; 38: 633-643.
45. Barros L, Ferreira C, Veldhoen M. The fellowship of regulatory and tissue-resident memory cells. Mucosal Immunol 2022; 15: 64-73.
46. Rosenblum MD, Way SS, Abbas AK. Regulatory T cell memory. Nat Rev Immunol 2016; 16: 90-101.
47. Sakaguchi S. Regulatory T cells: Key controllers of immunologic self-tolerance. Cell 2000; 101: 455-458.
48. Benoist C, Mathis D. Treg cells, life history, and diversity. Cold Spring Harb Perspect Biol 2012; 4: a007021.
49. Roncarolo MG, Gregori S, Bacchetta R, Battaglia M, Gagliani N. The biology of T regulatory type 1 cells and their therapeutic application in immune-mediated diseases. Immunity 2018; 49: 1004-1019.
50. Chen W, Jin W, Hardegen N, Lei KJ, Li L, Marinos N, et al. Conversion of peripheral CD4+CD25- naive T cells to CD4+CD25+ regulatory T cells by TGF-beta induction of transcription factor Foxp3. J Exp Med 2003; 198: 1875-1886.
51. Bordon Y. A new vein of TLR biology. Nat Rev Immunol 2010; 10: 748.
52. Floess S, Freyer J, Siewert C, Baron U, Olek S, Polansky J, et al. Epigenetic control of the foxp3 locus in regulatory T cells. PLoS Biol 2007; 5: e38.
53. Gratz IK, Truong HA, Yang SH, Maurano MM, Lee K, Abbas AK, et al. Cutting edge: Memory regulatory t cells require IL-7 and not IL-2 for their maintenance in peripheral tissues. J Immunol 2013; 190: 4483-4487.
54. Sanchez Rodriguez R, Pauli ML, Neuhaus IM, Yu SS, Arron ST, Harris HW, et al. Memory regulatory T cells reside in human skin. J Clin Invest 2014; 124: 1027-1036.
55. Fuhlbrigge RC, Kieffer JD, Armerding D, Kupper TS. Cutaneous lymphocyte antigen is a specialized form of PSGL-1 expressed on skin-homing T cells. Nature 1997; 389: 978-981.
56. Fukui M, Tager AM, Luster AD. Role of CCR4 and CCR8 in antigen specific T helper 2 cell trafficking into allergic lung. J Allergy Clin Immunol 2005; 115: S255.
57. Ali N, Zirak B, Rodriguez RS, Pauli ML, Truong HA, Lai K, et al. Regulatory T cells in skin facilitate epithelial stem cell differentiation. Cell 2017; 169: 1119-1129.
58. Arpaia N, Green JA, Moltedo B, Arvey A, Hemmers S, Yuan S, et al. A distinct function of regulatory T cells in tissue protection. Cell 2015; 162: 1078-1089.
59. Miragaia RJ, Gomes T, Chomka A, Jardine L, Riedel A, Hegazy AN, et al. Single-cell transcriptomics of regulatory T cells reveals trajectories of tissue adaptation. Immunity 2019; 50: 493-504.
60. Luo CT, Li MO. Transcriptional control of regulatory T cell development and function. Trends Immunol 2013; 34: 531-539.
61. Cretney E, Xin A, Shi W, Minnich M, Masson F, Miasari M, et al. The transcription factors Blimp-1 and IRF4 jointly control the differentiation and function of effector regulatory T cells. Nat Immunol 2011; 12: 304-311.
62. Wohlfert EA, Grainger JR, Bouladoux N, Konkel JE, Oldenhove G, Ribeiro CH, et al. GATA3 controls Foxp3(+) regulatory T cell fate during inflammation in mice. J Clin Invest 2011; 121: 4503-4515.
63. Michalek RD, Gerriets VA, Jacobs SR, Macintyre AN, MacIver NJ, Mason EF, et al. Cutting edge: Distinct glycolytic and lipid oxidative metabolic programs are essential for effector and regulatory CD4+ T cell subsets. J Immunol 2011; 186: 3299-3303.
64. Schneider A, Long SA, Kita M, Buckner JH. Persistence of FOXP3 expression is impaired in RR-MS Tregs (99.3). J Immunol 2009; 182: 99.3.
65. Komatsu N, Okamoto K, Sawa S, Nakashima T, Oh-hora M, Kodama T, et al. Pathogenic conversion of Foxp3+ T cells into TH17 cells in autoimmune arthritis. Nat Med 2014; 20: 62-68.
66. Blinova VG, Zhdanov DD. Many faces of regulatory T cells: Heterogeneity or plasticity? Cells 2024; 13: 959.
67. McCallion O, Bilici M, Hester J, Issa F. Regulatory T-cell therapy approaches. Clin Exp Immunol 2023; 211: 96-107.
68. Cheru N, Hafler DA, Sumida TS. Regulatory T cells in peripheral tissue tolerance and diseases. Front Immunol 2023; 14: 1154575.
69. Estrada Brull A, Panetti C, Joller N. Moving to the outskirts: Interplay between regulatory T cells and peripheral tissues. Front Immunol 2022; 13: 864628.
70. Santosh Nirmala S, Kayani K, Gliwiński M, Hu Y, Iwaszkiewicz-Grześ D, Piotrowska-Mieczkowska M, et al. Beyond FOXP3: A 20-year journey unravelling human regulatory T-cell heterogeneity. Front Immunol 2024; 14: 1321228.
71. Bennett CL, Christie J, Ramsdell F, Brunkow ME, Ferguson PJ, Whitesell L, et al. The immune dysregulation, polyendocrinopathy, enteropathy, X-linked syndrome (IPEX) is caused by mutations of FOXP3. Nat Genet 2001; 27:20- 21.
72. Wildin RS, Ramsdell F, Peake J, Faravelli F, Casanova J-L, Buist N, et al. X-linked neonatal diabetes mellitus, enteropathy and endocrinopathy syndrome is the human equivalent of mouse scurfy. Nat Genet 2001; 27: 18-20.
73. Joly AL, Seitz C, Liu S, Kuznetsov NV, Gertow K, Westerberg LS, et al. Alternative splicing of FOXP3 controls regulatory T cell effector functions and is associated with human atherosclerotic plaque stability. Circ Res 2018; 122: 1385-1394.
74. Chae WJ, Henegariu O, Lee SK, Bothwell AL. The mutant leucine-zipper domain impairs both dimerization and suppressive function of Foxp3 in T cells. Proc Natl Acad Sci U S A 2006; 103: 9631-9636.
75. Shevach EM. Mechanisms of foxp3+ T regulatory cell-mediated suppression. Immunity 2009; 30: 636-645.
76. Sakaguchi S, Mikami N, Wing JB, Tanaka A, Ichiyama K, Ohkura N. Regulatory T cells and human disease. Annu Rev Immunol 2020; 38: 541-566.
77. Moore KW, de Waal Malefyt R, Coffman RL, O’Garra A. Interleukin-10 and the interleukin-10 receptor. Annu Rev Immunol 2001; 19: 683-765.
78. Collison LW, Pillai MR, Chaturvedi V, Vignali DA. Regulatory T cell suppression is potentiated by target T cells in a cell contact, IL-35- and IL-10-dependent manner. J Immunol 2009; 182: 6121-6128.
79. Bluestone JA, Abbas AK. Natural versus adaptive regulatory T cells. Nat Rev Immunol 2003; 3: 253-257.
80. Qureshi OS, Zheng Y, Nakamura K, Attridge K, Manzotti C, Schmidt EM, et al. Trans-endocytosis of CD80 and CD86: A molecular basis for the cell-extrinsic function of CTLA-4. Science 2011; 332: 600-603.
81. Deshane J, Chaplin DD. Follicular dendritic cell makes environmental sense. Immunity 2010; 33: 2-4.
82. Ivanyi J, Plata F. Progess in antimicrobial immunity. Immune Regulation: Humana Press; 1985. p. 375-378.
83. Workman CJ, Vignali DA. Negative regulation of T cell homeostasis by lymphocyte activation gene-3 (CD223). J Immunol 2005; 174: 688-695.
84. Pandiyan P, Zheng L, Ishihara S, Reed J, Lenardo MJ. CD4+CD25+Foxp3+ regulatory T cells induce cytokine deprivation-mediated apoptosis of effector CD4+ T cells. Nat Immunol 2007; 8: 1353-1362.
85. Deaglio S, Dwyer KM, Gao W, Friedman D, Usheva A, Erat A, et al. Adenosine generation catalyzed by CD39 and CD73 expressed on regulatory T cells mediates immune suppression. J Exp Med 2007; 204: 1257-1265.
86. Angelin A, Gil-de-Gomez L, Dahiya S, Jiao J, Guo L, Levine MH, et al. Foxp3 reprograms T cell metabolism to function in low-glucose, high-lactate environments. Cell Metab 2017; 25: 1282-1293.
87. Weinberg SE, Sena LA, Chandel NS. Mitochondria in the regulation of innate and adaptive immunity. Immunity 2015; 42: 406-417.
88. Bordon Y. Asthma and allergy: The NET effect of respiratory viruses. Nat Rev Immunol 2017; 17: 346-347.
89. Fuchs O. Single-cell transcriptomics: Technology and applications. Single-Cell Omics: Elsevier; 2019. p. 231-251.
90. Bluestone JA. Chance favours the prepared mind. Nat Rev Immunol 2018; 18: 541.
91. Oshimori N, Fuchs E. Paracrine TGF-beta signaling counterbalances BMP-mediated repression in hair follicle stem cell activation. Cell Stem Cell 2012; 10: 63-75.
92. Paus R, Cotsarelis G. The biology of hair follicles. N Engl J Med 1999; 341: 491-497.
93. Nosbaum A, Prevel N, Truong HA, Mehta P, Ettinger M, Scharschmidt TC, et al. Cutting edge: Regulatory T cells facilitate cutaneous wound healing. J Immunol 2016; 196: 2010-2014.
94. Zaiss DM, van Loosdregt J, Gorlani A, Bekker CP, Grone A, Sibilia M, et al. Amphiregulin enhances regulatory T cell-suppressive function via the epidermal growth factor receptor. Immunity 2013; 38: 275-284.
95. Steenvoorde P, Oskam J. Comments on the paper, “The biosurgical wound debridement: Experimental investigation of efficiency and practicability,” by Blake FA et al. Wound Repair Regen. 2008; 16: 466.
96. Eming SA, Krieg T, Davidson JM. Inflammation in wound repair: Molecular and cellular mechanisms. J Invest Dermatol 2007; 127: 514-525.
97. Zaiss DMW, Gause WC, Osborne LC, Artis D. Emerging functions of amphiregulin in orchestrating immunity, inflammation, and tissue repair. Immunity 2015; 42: 216-226.
98. Smith AM, Moxon S, Morris GA. Biopolymers as wound healing materials. Wound Healing Biomaterials: Elsevier; 2016. p. 261-287.
99. Ono M, Yaguchi H, Ohkura N, Kitabayashi I, Nagamura Y, Nomura T, et al. Foxp3 controls regulatory T-cell function by interacting with AML1/Runx1. Nature 2007; 446: 685-689.
100. Fontenot JD, Rasmussen JP, Gavin MA, Rudensky AY. A function for interleukin 2 in Foxp3-expressing regulatory T cells. Nat Immunol 2005; 6: 1142-1151.
101. Brunkow ME, Jeffery EW, Hjerrild KA, Paeper B, Clark LB, Yasayko S-A, et al. Disruption of a new forkhead/winged-helix protein, scurfin, results in the fatal lymphoproliferative disorder of the scurfy mouse. Nat Genet 2001; 27: 68-73.
102. Li B, Song X, Zhou Z, Wang Q, Shen Y, Greene MI. FOXP3 activation in Treg cells, - atomic level aspects of FOXP3 structure and biochemistry that govern function (89.4). J Immunol 2009; 182: 89.4.
103. Zheng Y, Josefowicz SZ, Kas A, Chu TT, Gavin MA, Rudensky AY. Genome-wide analysis of Foxp3 target genes in developing and mature regulatory T cells. Nature 2007; 445: 936-940.
104. Martinez de Paz A, Josefowicz SZ. Gene regulatory networks STARR-ing B cells. Nat Immunol 2020; 21: 110-112.
105. Wu Y, Borde M, Heissmeyer V, Feuerer M, Lapan AD, Stroud JC, et al. FOXP3 controls regulatory T cell function through cooperation with NFAT. Cell 2006; 126: 375-387.
106. Wing K, Onishi Y, Prieto-Martin P, Yamaguchi T, Miyara M, Fehervari Z, et al. CTLA-4 control over Foxp3+ regulatory T cell function. Science 2008; 322: 271-275.
107. Cao X, Cai SF, Fehniger TA, Song J, Collins LI, Piwnica-Worms DR, et al. Granzyme B and perforin are important for regulatory T cell-mediated suppression of tumor clearance. Immunity 2007; 27: 635-646.
108. Soper DM, Kasprowicz DJ, Ziegler SF. IL-2Rbeta links IL-2R signaling with Foxp3 expression. Eur J Immunol 2007; 37: 1817-1826.
109. Zorn E, Nelson EA, Mohseni M, Porcheray F, Kim H, Litsa D, et al. IL-2 regulates FOXP3 expression in human CD4+ CD25+ regulatory T cells through a STAT-dependent mechanism and induces the expansion of these cells in vivo. Blood 2006; 108: 1571-1579.
110. Hayes SM, Li L, Love PE. TCR signal strength influences alphabeta/gammadelta lineage fate. Immunity 2005; 22: 583-593.
111. Park JW. Revised Pollen Calendar in Korea. Allergy Asthma Immunol Res. 2020; 12: 171-172.
112. Whalley K. Epigenetic regulation of asymmetry. Nat Rev Neurosci 2012; 13: 72.
113. Wilk C, Effenberg L, Abberger H, Steenpass L, Hansen W, Zeschnigk M, et al. CRISPR/Cas9-mediated demethylation of FOXP3-TSDR toward Treg-characteristic programming of Jurkat T cells. Cell Immunol 2022; 371: 104471.
114. Floess S, Freyer J, Siewert C, Baron U, Olek S, Polansky J, et al. Epigenetic control of the foxp3 locus in regulatory T cells. PLoS Biol 2007; 5: e38.
115. Barbon CM, Yang M, Wands GD, Ramesh R, Slusher BS, Hedley ML, et al. Consecutive low doses of cyclophosphamide preferentially target Tregs and potentiate T cell responses induced by DNA PLG microparticle immunization. Cell Immunol 2010; 262: 150-61.
116. Todd JA. Etiology of type 1 diabetes. Immunity 2010; 32: 457-67.
117. Pelling M, Garschagen M. Put equity first in climate adaptation. Nature 2019; 569: 327-329.
118. Zhang Z, Zhou X. Foxp3 Instability Helps tTregs Distinguish Self and Non-self. Front Immunol 2019; 10: 2226.
119. Zhou X, Bailey-Bucktrout S, Jeker LT, Bluestone JA. Plasticity of CD4+ FoxP3+ T cells. Curr Opin Immunol 2009; 21: 281-285.
120. Gudjonsson JE, Kabashima K, Eyerich K. Mechanisms of skin autoimmunity: Cellular and soluble immune components of the skin. J Allergy Clin Immunol 2020; 146: 8-16.
121. Miyao T, Floess S, Setoguchi R, Luche H, Fehling Hans J, Waldmann H, et al. Plasticity of Foxp3(+) T cells reflects promiscuous Foxp3 expression in conventional T cells but not reprogramming of regulatory T cells. Immunity 2012; 36: 262-275.
122. Bailey-Bucktrout SL, Bluestone JA. Regulatory T cells: Stability revisited. Trends Immunol 2011; 32: 301-306.
123. Miyao T, Floess S, Setoguchi R, Luche H, Fehling HJ, Waldmann H, et al. Plasticity of Foxp3+ T cells reflects promiscuous Foxp3 expression in conventional T cells but not reprogramming of regulatory T cells. Immunity 2012; 36: 262-275.
124. Furusawa Y, Obata Y, Fukuda S, Endo TA, Nakato G, Takahashi D, et al. Commensal microbe-derived butyrate induces the differentiation of colonic regulatory T cells. Nature 2013; 504: 446-450.
125. Kaelin WG, Jr., McKnight SL. Influence of metabolism on epigenetics and disease. Cell 2013; 153: 56-69.
126. Bending D, Ono M. FoxP3 partners up. Nat Immunol 2017; 18: 1181-1183.
127. van de Veen W, Wirz OF, Globinska A, Akdis M. Novel mechanisms in immune tolerance to allergens during natural allergen exposure and allergen-specific immunotherapy. Curr Opin Immunol 2017; 48: 74-81.
128. Nickoloff BJ, Qin JZ, Nestle FO. Immunopathogenesis of psoriasis. Clin Rev Allergy Immunol 2007; 33: 45-56.
129. Lee SE, Rudd BD, Smith NL. Fate-mapping mice: New tools and technology for immune discovery. Trends Immunol 2022; 43: 195-209.
130. Seibler J, Zevnik B, Küter-Luks B, Andreas S, Kern H, Hennek T, et al. Rapid generation of inducible mouse mutants. Nucleic Acids Res 2003; 31: e12.
131. Zhang B, Wu J, Jiao Y, Bock C, Dai M, Chen B, et al. Differential requirements of TCR signaling in homeostatic maintenance and function of dendritic epidermal T cells. J Immunol 2015; 195: 4282-4291.
132. Davoodi-Semiromi A, Cheikhi A, Xia C, Litherland S, Clare-Salzler M. Modulation of CD4+Foxp3− T-cells with a JAK-STAT5 kinase inhibitor (131.2). J Immunol 2007; 178: S237.
133. Yang F, Ikeda Y, Guo Z, Bednar KJ. Regulatory T cell heterogeneity: Who they are, where they come from, and where they go. Front Immunol 2026; 17: 1929923.
134. Ohkura N, Sakaguchi S. Foxo1 and Foxo3 help Foxp3. Immunity 2010; 33: 835-837.
135. Ouyang W, Beckett O, Ma Q, Paik JH, DePinho RA, Li MO. Foxo proteins cooperatively control the differentiation of Foxp3+ regulatory T cells. Nat Immunol 2010; 11: 618-627.
136. Kerdiles YM, Stone EL, Beisner DL, McGargill MA, Ch’en IL, Stockmann C, et al. Foxo transcription factors control regulatory T cell development and function. Immunity 2010; 33: 890-904.
137. Gamper CJ, Powell JD. All PI3Kinase signaling is not mTOR: Dissecting mTOR-dependent and independent signaling pathways in T cells. Front Immunol 2012; 3: 312.
138. Sen R. The origins of NF-kappaB. Nat Immunol 2011; 12: 686-688.
139. Gerondakis S, Fulford TS, Messina NL, Grumont RJ. NF-kappaB control of T cell development. Nat Immunol 2014; 15: 15-25.
140. Zhang F, Meng G, Strober W. Erratum: Corrigendum: Interactions among the transcription factors Runx1, RORγ t and Foxp3 regulate the differentiation of interleukin 17–producing T cells. Nat Immunol 2009; 10: 223.
141. Targeting the c-Rel Subunit of NF-κB Inhibits Treg Function in Melanoma. Cancer Discov 2017; 7: OF13.
142. Sawant DV, Vignali DA. Once a Treg, always a Treg? Immunol Rev 2014; 259: 173-191.
143. Huehn J, Siegmund K, Lehmann JC, Siewert C, Haubold U, Feuerer M, et al. Developmental stage, phenotype, and migration distinguish naive- and effector/memory-like CD4+ regulatory T cells. J Exp Med 2004; 199: 303-313.
144. Campbell DJ, Koch MA. Phenotypical and functional specialization of FOXP3+ regulatory T cells. Nat Rev Immunol 2011; 11: 119-130.
145. Koch MA, Tucker-Heard G, Perdue NR, Killebrew JR, Urdahl KB, Campbell DJ. The transcription factor T-bet controls regulatory T cell homeostasis and function during type 1 inflammation. Nat Immunol 2009; 10: 595-602.
146. Schmidl C, Klug M, Boeld TJ, Andreesen R, Hoffmann P, Edinger M, et al. Lineage-specific DNA methylation in T cells correlates with histone methylation and enhancer activity. Genome Res 2009; 19: 1165-1174.
147. Scharschmidt TC, Vasquez KS, Truong H-A, Gearty SV, Pauli ML, Nosbaum A, et al. A wave of regulatory T cells into neonatal skin mediates tolerance to commensal microbes. Immunity 2015; 43: 1011-1021.
148. Angelin A, Gil-de-Gómez L, Dahiya S, Jiao J, Guo L, Levine MH, et al. Foxp3 reprograms T cell metabolism to function in low-glucose, high-lactate environments. Cell Metab 2017; 25: 1282-1293.
149. Beier UH, Wang L, Han R, Akimova T, Liu Y, Hancock WW. Histone deacetylases 6 and 9 and sirtuin-1 control Foxp3+ regulatory T cell function through shared and isoform-specific mechanisms. Sci Signal 2012; 5: ra45.
150. Liu Y, Wang L, Han R, Beier UH, Hancock WW. Two lysines in the forkhead domain of foxp3 are key to T regulatory cell function. PloS One 2012; 7: e29035.
151. Howie D, Cobbold SP, Adams E, Ten Bokum A, Necula AS, Zhang W, et al. Foxp3 drives oxidative phosphorylation and protection from lipotoxicity. JCI Insight 2017; 2: e89160.
152. Cully M. Autoimmunity: LKB1 helps T(reg) cells battle exhaustion. Nat Rev Immunol 2017; 17: 592-593.
153. Pola C. Muscular Treg cells. Nat Med 2014; 20: 28.
154. Carbone F, De Rosa V, Carrieri PB, Montella S, Bruzzese D, Porcellini A, et al. Regulatory T cell proliferative potential is impaired in human autoimmune disease. Nat Med 2014; 20: 69-74.
155. Levy-Lahad E, Wildin RS. Neonatal diabetes mellitus, enteropathy, thrombocytopenia, and endocrinopathy: Further evidence for an X-linked lethal syndrome. J Pediatr 2001; 138: 577-580.
156. Immune Dysregulation, Polyendocrinopathy, Enteropathy, X-linked Syndrome.  SpringerReference: Springer-Verlag; 2011.
157. Bacchetta R, Passerini L, Gambineri E, Dai M, Allan SE, Perroni L, et al. Defective regulatory and effector T cell functions in patients with FOXP3 mutations. J Clin Invest 2006; 116: 1713-1722.
158. Gambineri E, Hackett M, Añover S, Zhu Q, Ocheltree E, Ochs HD, et al. Clinical, laboratory, and molecular evaluation of 105 patients with a phenotype of immune dysregulation, polyendocrinopathy, enteropathy, X-linked (IPEX) syndrome. J Allergy Clin Immunol 2009; 123: S148.
159. d’Hennezel E, Piccirillo CA. Analysis of human FOXP3+ Treg Cells Phenotype and Function. Methods in Molecular Biology: Humana Press; 2011. p. 199-218.
160. d’Hennezel E, Ben-Shoshan M, Ochs HD, Torgerson TR, Russell LJ, Lejtenyi C, et al. FOXP3 forkhead domain mutation and regulatory T cells in the IPEX syndrome. N Engl J Med 2009; 361: 1710-1713.
161. Barzaghi F, Passerini L, Bacchetta R. Immune dysregulation, polyendocrinopathy, enteropathy, x-linked syndrome: A paradigm of immunodeficiency with autoimmunity. Front Immunol 2012; 3: 211.
162. Session 02: Regulatory T cells. Immunology 2008; 104: 6-13.
163. Szczawińska-Popłonyk A. Atopic dermatitis in inborn errors of immunity: At the interface of immunodeficiency and immune dysregulation. Immunol Res 2025; 73: 147.
164. Bakhtiar S, Ghosh S, Hauck F. Diseases of Immune Dysregulation.  Inborn Errors of Immunity: Definition, Diagnosis, and Management: Springer; 2026. p. 407-88.
165. Gambineri E, Ciullini Mannurita S, Hagin D, Vignoli M, Anover-Sombke S, DeBoer S, et al. Clinical, immunological, and molecular heterogeneity of 173 patients with the phenotype of immune dysregulation, polyendocrinopathy, enteropathy, X-linked (IPEX) syndrome. Front Immunol 2018; 9: 2411.
166. Li D, McIntosh CS, Mastaglia FL, Wilton SD, Aung-Htut MT. Neurodegenerative diseases: A hotbed for splicing defects and the potential therapies. Transl Neurodegener 2021; 10: 16.
167. Zong X, Hao X, Xu B, Crawford JC, Wright S, Li J, et al. Foxp3 enhancers synergize to maximize regulatory T cell suppressive capacity. J Exp Med 2021; 218: e20202415.
168. Aljubran S, Al najem A. An early successful hematopoietic stem cell transplant (Hsct) for a boy with ipex syndrome. Ann Allergy Asthma Immunol 2024; 133: S171.
169. Spickett GP. Chapter 9 Autoimmune haematological disorders. Oxford Handbook of Clinical Immunology and Allergy: Oxford University Press; 2006.
170. Resnick ES. X‐linked Immune Dysregulation with Polyendocrinopathy (IPEX) Syndrome. Allergy and Clinical Immunology: Wiley; 2015. p. 382-7.
171. Sontheimer RD. Subacute cutaneous lupus erythematosus: 25-year evolution of a prototypic subset (subphenotype) of lupus erythematosus defined by characteristic cutaneous, pathological, immunological, and genetic findings. Autoimmun Rev 2005; 4: 253-263.
172. Naguib G, Al-Mashat H, Desta T, Graves DT. Diabetes prolongs the inflammatory response to a bacterial stimulus through cytokine dysregulation. J Invest Dermatol 2004; 123: 87-92.
173. Changelian PS, Moshinsky D, Kuhn CF, Flanagan ME, Munchhof MJ, Harris TM, et al. The specificity of JAK3 kinase inhibitors. Blood 2008; 111: 2155-22157.
174. Barzaghi F, Passerini L. IPEX syndrome: Improved knowledge of immune pathogenesis empowers diagnosis. Front Pediatr 2021; 9: 612760.
175. Fisher MS, Sennikov SV. T-regulatory cells for the treatment of autoimmune diseases. Front Immunol 2025; 16: 1511671.
176. Cepika A-M, Sato Y, Liu JM-H, Uyeda MJ, Bacchetta R, Roncarolo MG. Tregopathies: Monogenic diseases resulting in regulatory T-cell deficiency. JAllergy Clin Immunol 2018; 142: 1679-1695.
177. Su HC. Dedicator of cytokinesis 8 (DOCK8) deficiency. Curr Opin Allergy Clin Immunol 2010; 10: 515-520.
178. Gates MG, Atkinson TP. Transient hypereosinophilia and markedly elevated IgE as the presenting feature in DOCK8 (Dedicator of Cytokinesis 8) deficiency. J Allergy Clin Immunol 2012; 129: AB159.
179. Randall K, Lambe T, Johnson A, Kucharska E, Vinuesa C, Treanor B, et al. Immunodeficiency and abnormal B cell synapse formation due to DOCK8 mutations in mice. Clin Immunol 2010; 135: S17.
180. Simpson EL, Bieber T, Guttman-Yassky E, Beck LA, Blauvelt A, Cork MJ, et al. Two phase 3 trials of dupilumab versus placebo in atopic dermatitis. N Engl J Med 2016; 375: 2335-2348.
181. Maiarana J, Moncada-Velez M, Malbran E, Torre MG, Elonen C, Malbran A, et al. Deep immunophenotyping shows altered immune cell subsets in CTLA‐4 haploinsufficiency. Pediatr Allergy Immunol 2023; 34: e13994.
182. Pichler WJ. Drug-induced autoimmunity. Curr Opin Allergy Clin Immunol 2003; 3: 249-253.
183. Hossen MM, Ma Y, Yin Z, Xia Y, Du J, Huang JY, et al. Current understanding of CTLA-4: From mechanism to autoimmune diseases. Front Immunol 2023; 14: 1198365.
184. Sangiorgi E, Capecchi MR. Bmi1 is expressed in vivo in intestinal stem cells. Nat Genet 2008; 40: 915-920.
185. Al-Awqati Q. Kidney growth and hypertrophy: The role of mTOR and vesicle trafficking. J Clin Invest 2015; 125: 2267-2270.
186. Suh YW, Horton JC. Papilledema from gain-of-function mutations in the STAT3 gene. Ophthalmic Genet 2019; 40: 165-9.
187. Furuta GT, Katzka DA. Eosinophilic esophagitis. N Engl J Med 2015; 373: 1640-1648.
188. Kıykım A. STAT1/STAT3 gain of function and mechanisms of immune dysregulation. Turkish J Immunol 2024; 12: 47-52.
189. Ochs HD, Thrasher AJ. The wiskott-aldrich syndrome. J Allergy Clin Immunol 2006; 117: 725-738.
190. Metcalf D. On hematopoietic stem cell fate. Immunity 2007; 26: 669-673.
191. Humblet-Baron S, Sather B, Anover S, Becker-Herman S, Kasprowicz DJ, Khim S, et al. Wiskott-aldrich syndrome protein is required for regulatory T cell homeostasis. J Clin Invest 2007; 117: 407-418.
192. Lee G, Chung H-S, Lee K, Lee H, Kim M, Bae H. Curcumin attenuates the scurfy-induced immune disorder, a model of IPEX syndrome, with inhibiting Th1/Th2/Th17 responses in mice. Phytomedicine 2017; 33: 1-6.
193. Zheng C, Shi Y, Zou Y. T cell co-stimulatory and co-inhibitory pathways in atopic dermatitis. Front Immunol 2023; 14: 1081999.
194. Gámez-Díaz L, Grimbacher B. Immune checkpoint deficiencies and autoimmune lymphoproliferative syndromes. biomed J 2021; 44: 400-411.
195. Biggs CM, Keles S, Chatila TA. DOCK8 deficiency: Insights into pathophysiology, clinical features and management. Clin Immunol 2017; 181: 75-82.
196. Calautti E, Avalle L, Poli V. Psoriasis: A STAT3-centric view. Int J Mol Sci 2018; 19: 171.
197. Kalekar LA, Rosenblum MD. Regulatory T cells in inflammatory skin disease: From mice to humans. Int Immunol 2019; 31: 457-463.
198. Bacchetta R, Roncarolo MG. IPEX syndrome from diagnosis to cure, learning along the way. J Allergy Clin Immunol 2024; 153: 595-605.
199. Kennedy-Batalla R, Acevedo D, Luo Y, Esteve-Solé A, Vlagea A, Correa-Rocha R, et al. Treg in inborn errors of immunity: Gaps, knowns and future perspectives. Front Immunol 2024; 14: 1278759.
200. Tong X, Kim SH, Che L, Park J, Lee J, Kim TG. Foxp3(+) Treg control allergic skin inflammation by restricting IFN-γ-driven neutrophilic infiltration and NETosis. J Dermatol Sci 2024; 115: 2-12.
201. Hardtke-Wolenski M, Landwehr-Kenzel S. Tipping the balance in autoimmunity: Are regulatory t cells the cause, the cure, or both? Mol Cell Pediatr 2024; 11: 3.
202. Visan I. Restricting T cell responses. Nat Immunol 2013; 14:691.
203. Bieber T. Atopic dermatitis. N Engl J Med 2008; 358: 1483-1494.
204. Lowes MA, Suarez-Farinas M, Krueger JG. Immunology of psoriasis. Annu Rev Immunol 2014; 32: 227-255.
205. Ginhoux F, Guilliams M, Merad M. Expanding dendritic cell nomenclature in the single-cell era. Nat Rev Immunol 2022; 22: 67-68.
206. Kirschner N, Houdek P, Fromm M, Moll I, Brandner JM. Tight junctions form a barrier in human epidermis. Eur J Cell Biol 2010; 89: 839-842.
207. Gittler JK, Krueger JG, Guttman-Yassky E. Atopic dermatitis results in intrinsic barrier and immune abnormalities: implications for contact dermatitis. J Allergy Clin Immunol 2013; 131: 300-313.
208. Arpaia N, Green JA, Moltedo B, Arvey A, Hemmers S, Yuan S, et al. A distinct function of regulatory T cells in tissue protection. Cell 2015; 162: 1078-1089.
209. Weaver CT, Hatton RD, Mangan PR, Harrington LE. IL-17 family cytokines and the expanding diversity of effector T cell lineages. Annu Rev Immunol 2007; 25: 821-852.
210. Beres A, Komorowski R, Mihara M, Drobyski WR. Instability of Foxp3 expression limits the ability of induced regulatory T cells to mitigate graft versus host disease. Clin Cancer Res 2011; 17: 3969-3983.
211. Lou H, Lu J, Choi EB, Oh MH, Jeong M, Barmettler S, et al. Expression of IL-22 in the skin causes Th2-biased immunity, epidermal barrier dysfunction, and pruritus via stimulating epithelial Th2 cytokines and the GRP pathway. J Immunol 2017; 198: 2543-2555.
212. Liwinski T, Zheng D, Elinav E. The microbiome and cytosolic innate immune receptors. Immunol Rev 2020; 297: 207-224.
213. Soto‐Heredero G, Gómez de Las Heras MM, Gabandé‐Rodríguez E, Oller J, Mittelbrunn M. Glycolysis–a key player in the inflammatory response. FEBS J 2020; 287: 3350-3369.
214. Zaiss DM, Gause WC, Osborne LC, Artis D. Emerging functions of amphiregulin in orchestrating immunity, inflammation, and tissue repair. Immunity 2015; 42: 216-226.